LARP6

Summary

LARP6 (La ribonucleoprotein 6, translational regulator, HGNC:24012) is a protein-coding gene on chromosome 15q23, encoding La-related protein 6 (Q9BRS8). Regulates the coordinated translation of type I collagen alpha-1 and alpha-2 mRNAs, CO1A1 and CO1A2.

Enables RNA binding activity and myosin binding activity. Involved in positive regulation of collagen biosynthetic process. Located in cytoplasm and nucleus.

Source: NCBI Gene 55323 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 81 total
• Druggable target: yes
• MANE Select transcript: NM_018357

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24012
Approved symbol	LARP6
Name	La ribonucleoprotein 6, translational regulator
Location	15q23
Locus type	gene with protein product
Status	Approved
Aliases	acheron, FLJ11196
Ensembl gene	ENSG00000166173
Ensembl biotype	protein_coding
OMIM	611300
Entrez	55323

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000299213, ENST00000344870, ENST00000559140, ENST00000559316, ENST00000560052

RefSeq mRNA: 2 — MANE Select: NM_018357 NM_018357, NM_197958

CCDS: CCDS10236, CCDS32281

Canonical transcript exons

ENST00000299213 — 3 exons

Exon	Start	End
ENSE00001100511	70853889	70854157
ENSE00001122584	70829130	70833116
ENSE00003520649	70836295	70836505

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 98.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 68.1071 / max 600.0407, expressed in 1474 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150738	59.6324	1474
150737	6.3826	1292
150736	1.4889	774
150739	0.5107	303
150735	0.0507	5
150734	0.0418	4

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral globus pallidus	UBERON:0002476	98.11	gold quality
inferior vagus X ganglion	UBERON:0005363	97.66	gold quality
mucosa of stomach	UBERON:0001199	97.61	gold quality
left testis	UBERON:0004533	97.55	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.33	gold quality
right testis	UBERON:0004534	97.25	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.16	gold quality
spinal cord	UBERON:0002240	96.82	gold quality
subthalamic nucleus	UBERON:0001906	96.79	gold quality
inferior olivary complex	UBERON:0002127	96.56	gold quality
dorsal plus ventral thalamus	UBERON:0001897	96.32	gold quality
substantia nigra pars reticulata	UBERON:0001966	96.00	gold quality
medulla oblongata	UBERON:0001896	95.97	gold quality
pons	UBERON:0000988	95.92	gold quality
putamen	UBERON:0001874	95.74	gold quality
ventral tegmental area	UBERON:0002691	95.73	gold quality
sperm	CL:0000019	95.61	gold quality
substantia nigra pars compacta	UBERON:0001965	95.58	gold quality
superior vestibular nucleus	UBERON:0007227	95.57	gold quality
testis	UBERON:0000473	95.38	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	95.25	gold quality
midbrain	UBERON:0001891	95.23	gold quality
substantia nigra	UBERON:0002038	95.14	gold quality
prefrontal cortex	UBERON:0000451	95.13	gold quality
stromal cell of endometrium	CL:0002255	95.06	gold quality
corpus callosum	UBERON:0002336	94.97	gold quality
middle temporal gyrus	UBERON:0002771	94.56	gold quality
Ammon’s horn	UBERON:0001954	94.48	gold quality
caudate nucleus	UBERON:0001873	94.29	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.29	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9435	yes	1081.94
E-HCAD-13	yes	24.99
E-ANND-3	yes	20.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting LARP6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-609	99.82	64.26	505
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-7515	99.31	68.22	1795
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-6715B-3P	98.80	68.07	1204
HSA-MIR-876-3P	98.76	68.23	945
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-4704-3P	98.28	69.33	1300
HSA-MIR-643	97.35	67.91	805
HSA-MIR-215-3P	97.02	68.01	1209
HSA-MIR-6854-5P	96.77	65.96	848
HSA-MIR-4264	96.35	64.76	1480
HSA-MIR-3677-5P	93.16	64.62	393
HSA-MIR-126-3P	91.07	64.87	22

Literature-anchored findings (GeneRIF, showing 16)

• These data define Achn as a newly discovered regulatory molecule that presumably mediates a variety of developmental and homeostatic processes in animals. (PMID:17383118)
• Acheron may influence differentiation in part via its control of cell adhesion dynamics. (PMID:19889961)
• LARP6 has a distinctive bipartite RNA binding domain not found in other members of the La superfamily. LARP6 interacts with the two single-stranded regions of the 5’ stem-loop. (PMID:19917293)
• Achn enhances human breast tumor growth and vascularization and that this activity is dependent on nuclear localization. (PMID:21387291)
• Acheron regulates vascular endothelial proliferation and angiogenesis together with Id1 during wound healing. (PMID:22139627)
• The results demonstrate that the La modules of the human LARP6 is also active in tRNA-mediated suppression, even in the absence of stable UUU-3’OH trailer protection. (PMID:23887937)
• LARP6 is a critical mediator by which IGF-1 augments synthesis of collagen type I in vascular smooth muscle (PMID:24469459)
• We postulate that collagen mRNAs directly partition to the endoplasmic reticulum membrane prior to synthesis of the signal peptide and that LARP6 and nonmuscle myosin filaments mediate this process. (PMID:25271881)
• The study presents the structure of the La motif and RRM1 of human LARP6 uncovering in both cases considerable structural variation in comparison to the equivalent domains in La and revealing an unprecedented fold for the RRM1. (PMID:25488812)
• Data indicate that LA motif protein LARP6 binding to spliced leader RNA (5’SL) of collagen alpha2(I) mRNA is more stable than the binding to 5’SL of alpha1(I) mRNA. (PMID:25692237)
• Akt mediated phosphorylation of LARP6; critical step in biosynthesis of type I collagen (PMID:26932461)
• Study shows that mTORC1 phosphorylates La ribonucleoprotein domain family, member 6 to stimulate type I collagen expression. (PMID:28112218)
• A cytoplasmic isoform of La protein as well as LARPs 6, 4, and 1 function in mRNA metabolism and translation in distinct but similar ways, sometimes with the poly(A)-binding protein, and in some cases by direct binding to poly(A)-RNA. (PMID:28782243)
• Characterization of Sequence-Specific Binding of LARP6 to the 5’ Stem-Loop of Type I Collagen mRNAs and Implications for Rational Design of Antifibrotic Drugs. (PMID:34896113)
• LARP6 Regulates Keloid Fibroblast Proliferation, Invasion, and Ability to Synthesize Collagen. (PMID:35176288)
• LARP6 suppresses colorectal cancer progression through ZNF267/SGMS2-mediated imbalance of sphingomyelin synthesis. (PMID:36691044)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	larp6a	ENSDARG00000005355
mus_musculus	Larp6	ENSMUSG00000034839
rattus_norvegicus	Larp6	ENSRNOG00000012438
drosophila_melanogaster	Larp4B	FBGN0035424
drosophila_melanogaster	larp	FBGN0261618
caenorhabditis_elegans	larp-5	WBGENE00004147
caenorhabditis_elegans		WBGENE00020097

Paralogs (6): LARP4B (ENSG00000107929), SSB (ENSG00000138385), LARP1B (ENSG00000138709), LARP1 (ENSG00000155506), LARP4 (ENSG00000161813), LARP7 (ENSG00000174720)

Protein

Protein identifiers

La-related protein 6 — Q9BRS8 (reviewed: Q9BRS8)

Alternative names: Acheron, La ribonucleoprotein domain family member 6

All UniProt accessions (3): Q9BRS8, H0YMC6, K7EPD2

UniProt curated annotations — full annotation on UniProt →

Function. Regulates the coordinated translation of type I collagen alpha-1 and alpha-2 mRNAs, CO1A1 and CO1A2. Stabilizes mRNAs through high-affinity binding of a stem-loop structure in their 5’ UTR. This regulation requires VIM and MYH10 filaments, and the helicase DHX9.

Subunit / interactions. Interacts (via the HTH domain) with VIM/vimentin. Interacts (via C-terminus) with non-muscle myosin MYH10. Interacts (via C-terminus) with DHX9.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in numerous tissues.

Domain organisation. The RRM domain mediates the association with collagen mRNAs stem-loops.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BRS8-1	1	yes
Q9BRS8-2	2

RefSeq proteins (2): NP_060827, NP_932062 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002344	Lupus_La	Family
IPR006630	La_HTH	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR024642	SUZ-C	Domain
IPR034880	LARP6_RRM	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR045180	La_dom_prot	Family

Pfam: PF05383, PF12901

UniProt features (44 total): strand 8, helix 8, turn 8, compositionally biased region 5, modified residue 3, domain 3, region of interest 3, short sequence motif 2, initiator methionine 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
2MTF	SOLUTION NMR
2MTG	SOLUTION NMR
9NGX	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRS8-F1	61.16	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 2, 56, 58

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 109 (showing top): BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, MENSE_HYPOXIA_UP, DITTMER_PTHLH_TARGETS_UP, MODULE_493, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, BASAKI_YBX1_TARGETS_UP, DOUGLAS_BMI1_TARGETS_UP, chr15q23, VECCHI_GASTRIC_CANCER_EARLY_DN, HAN_SATB1_TARGETS_DN, LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP

GO Biological Process (3): RNA processing (GO:0006396), regulation of translation (GO:0006417), positive regulation of collagen biosynthetic process (GO:0032967)

GO Molecular Function (8): mRNA binding (GO:0003729), myosin binding (GO:0017022), RNA stem-loop binding (GO:0035613), mRNA 5’-UTR binding (GO:0048027), sequence-specific mRNA binding (GO:1990825), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), ribonucleoprotein complex (GO:1990904)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA binding	2
mRNA binding	2
binding	2
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
translation	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
positive regulation of biosynthetic process	1
positive regulation of collagen metabolic process	1
collagen biosynthetic process	1
regulation of collagen biosynthetic process	1
cytoskeletal protein binding	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
protein-containing complex	1

Protein interactions and networks

STRING

576 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LARP6	LARP4B	Q92615	742
LARP6	LARP4	Q71RC2	725
LARP6	STRAP	Q9Y3F4	618
LARP6	DHX9	Q08211	606
LARP6	TM2D3	Q9BRN9	514
LARP6	CSDE1	O75534	491
LARP6	MAB21L3	Q8N8X9	488
LARP6	PABPC1	P11940	470
LARP6	FKBP3	Q00688	460
LARP6	NKX6-3	A6NJ46	444
LARP6	GMNC	A6NCL1	436
LARP6	ODAD4	Q96NG3	434
LARP6	SLC35D3	Q5M8T2	433
LARP6	SLC30A8	Q8IWU4	424
LARP6	LRRC49	Q8IUZ0	418
LARP6	PEX5L	Q8IYB4	418

IntAct

5 interactions, top by confidence:

A	B	Type	Score
STRAP	CDK2AP1	psi-mi:“MI:0914”(association)	0.530
STRAP	GEMIN2	psi-mi:“MI:0914”(association)	0.350
ADARB1	LARP6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): LARP6 (Affinity Capture-MS), LARP6 (Protein-RNA), LARP6 (Protein-RNA), LARP6 (Proximity Label-MS), LARP6 (Affinity Capture-MS), LARP6 (Reconstituted Complex), LARP6 (Two-hybrid), ITSN2 (Cross-Linking-MS (XL-MS)), DNAJC11 (Cross-Linking-MS (XL-MS)), DNAJC18 (Cross-Linking-MS (XL-MS)), LARP6 (Cross-Linking-MS (XL-MS)), LARP6 (Cross-Linking-MS (XL-MS)), LARP6 (Two-hybrid), APP (Reconstituted Complex)

ESM2 similar proteins: A0JNJ1, A5PMU4, A6QQV9, A7E3S4, D4AB98, F7EL49, P15056, P34908, P59672, P97306, Q04982, Q13905, Q15678, Q16825, Q5F488, Q5TCQ9, Q5TCZ1, Q62130, Q62136, Q62728, Q6DD51, Q6H8Q1, Q6KC51, Q6P9K8, Q6ZMT1, Q80T23, Q80YS6, Q812E4, Q8BL65, Q8BN59, Q8BZ71, Q8BZI0, Q8N556, Q8R1B0, Q8TDW5, Q8TED9, Q8TEW8, Q8VH46, Q8VHK2, Q8WXD9

Diamond homologs: D5MCN2, J9VT60, O80567, P05455, P10881, P25567, P28048, P28049, P32067, P33399, P38656, P40796, Q05CL8, Q12034, Q26457, Q28G87, Q4G0J3, Q4R627, Q5XI01, Q659C4, Q6PKG0, Q6ZQ58, Q71RC2, Q7ZWE3, Q8BN59, Q8BWW4, Q8RWR2, Q94A38, Q94K80, Q9BRS8, Q9I7T7, Q9LHL3, Q9P6K0, Q9VAW5, P87058, Q04504, Q940X9, Q0V7U7, Q93ZV7, Q6A0A2

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
LARP6	“up-regulates activity”	DHX9	binding
AKT	“up-regulates activity”	LARP6	phosphorylation
AKT1	“up-regulates activity”	LARP6	phosphorylation
VIM	“up-regulates activity”	LARP6	binding
MTOR	“up-regulates activity”	LARP6	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

331 predictions. Top by Δscore:

Variant	Effect	Δscore
15:70833117:C:CA	acceptor_loss	1.0000
15:70833118:T:A	acceptor_loss	1.0000
15:70836291:TCA:T	donor_loss	1.0000
15:70836292:CACC:C	donor_loss	1.0000
15:70836293:A:AT	donor_loss	1.0000
15:70836294:CCTTT:C	donor_loss	1.0000
15:70836501:TGCCA:T	acceptor_gain	1.0000
15:70836502:GCCA:G	acceptor_gain	1.0000
15:70836503:CCA:C	acceptor_gain	1.0000
15:70836503:CCAC:C	acceptor_gain	1.0000
15:70836504:CA:C	acceptor_gain	1.0000
15:70836504:CAC:C	acceptor_gain	1.0000
15:70836505:ACTGA:A	acceptor_loss	1.0000
15:70836506:C:CC	acceptor_gain	1.0000
15:70836506:CTGA:C	acceptor_loss	1.0000
15:70836513:C:CT	acceptor_gain	1.0000
15:70836513:C:T	acceptor_gain	1.0000
15:70836514:A:T	acceptor_gain	1.0000
15:70833114:CAC:C	acceptor_gain	0.9900
15:70833117:C:CC	acceptor_gain	0.9900
15:70836328:A:C	donor_gain	0.9900
15:70836345:T:TA	donor_gain	0.9900
15:70853886:TA:T	donor_loss	0.9900
15:70853888:C:CA	donor_loss	0.9900
15:70853991:T:TA	donor_gain	0.9900
15:70833113:TCAC:T	acceptor_gain	0.9800
15:70833114:CACC:C	acceptor_gain	0.9800
15:70833120:C:CT	acceptor_gain	0.9800
15:70833121:A:T	acceptor_gain	0.9800
15:70836293:A:AC	donor_gain	0.9800

AlphaMissense

3244 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:70833021:C:A	R169S	1.000
15:70833021:C:G	R169S	1.000
15:70833022:C:A	R169M	1.000
15:70833022:C:G	R169T	1.000
15:70833055:A:T	L158H	1.000
15:70833073:A:C	L152W	1.000
15:70833076:G:T	A151D	1.000
15:70833095:A:G	W145R	1.000
15:70833095:A:T	W145R	1.000
15:70833111:T:A	K139N	1.000
15:70833111:T:G	K139N	1.000
15:70833113:T:C	K139E	1.000
15:70836302:A:G	F135S	1.000
15:70836311:A:G	L132P	1.000
15:70836311:A:T	L132H	1.000
15:70836314:A:G	L131P	1.000
15:70836314:A:T	L131Q	1.000
15:70836316:C:A	K130N	1.000
15:70836316:C:G	K130N	1.000
15:70836318:T:C	K130E	1.000
15:70836320:A:T	V129D	1.000
15:70836322:G:C	S128R	1.000
15:70836322:G:T	S128R	1.000
15:70836324:T:G	S128R	1.000
15:70836326:A:T	V127E	1.000
15:70836332:C:A	G125V	1.000
15:70836332:C:T	G125E	1.000
15:70836333:C:G	G125R	1.000
15:70836333:C:T	G125R	1.000
15:70836343:C:A	R121S	1.000

dbSNP variants (sampled 300 via entrez): RS1000144874 (15:70855394 T>G), RS1000205198 (15:70847955 A>G), RS1000239839 (15:70841014 T>C), RS1000337405 (15:70834048 G>A,C), RS1000390085 (15:70834419 G>A,T), RS1000429168 (15:70837672 T>A), RS1000495710 (15:70855097 G>A), RS1000592140 (15:70840713 A>G), RS1000626345 (15:70843719 G>C), RS1000669889 (15:70849562 A>T), RS1000980316 (15:70846274 T>C), RS1001056340 (15:70855776 G>C), RS1001095592 (15:70852932 G>A), RS1001183905 (15:70830386 A>C), RS1001353056 (15:70847233 T>C)

Disease associations

OMIM: gene MIM:611300 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001212_6	Proinsulin levels	2.000000e-10
GCST009863_24	Insulin-related traits (multivariate analysis)	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004467	insulin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4739702 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	9
Benzo(a)pyrene	increases expression, increases methylation	4
Cyclosporine	increases expression	4
sodium arsenite	decreases expression, increases expression	3
Acetaminophen	increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Cisplatin	affects expression, decreases expression	2
Dexamethasone	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
Tunicamycin	increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
methylparaben	increases expression	1
o,p’-DDT	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
ICG 001	increases expression	1
CC-8490	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases expression	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4689799	Binding	Inhibition of LARP6 La module (unknown origin) binding with collagen 5’ stem loop mRNA at > 2.5 uM by gel mobility shift assay	Discovery of a Lead Compound for Specific Inhibition of Type I Collagen Production in Fibrosis. — ACS Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.